(Total Views: 851)
Posted On: 01/25/2021 1:07:18 AM
Post# of 148897
More German coverage of leronlimab; saw this on lieHub (moneycrew) and don't think it's been shared over here:
https://www.vfa.de/de/englische-inhalte/thera...s-covid-19
17. January 2021
Therapeutic medicines against the coronavirus infection Covid-19
"The active ingredient Leronlimab from CytoDyn is a CCR5 antagonist, it blocks a receptor on the surface of certain immune cells. In a phase II trial, it was shown to improve the health of mild to moderate Covid-19 patients. The manufacturer then conducted a Phase III trial in patients with severe disease and applied to the FDA for emergency use approval. Until a decision is made, new patients with severe symptoms at the hospitals that participated in the trial can be treated with Leronlimab. The company is also testing whether Leronlimab will improve late symptoms in Covid 19 patients who have had the infection for a long time. The antibody Leronlimab has long been developed for the treatment of HIV and triple-negative breast cancer, for which it is already being tested in trials. However, its efficacy against HIV is not based on attenuating immunomodulation, but on the fact that the active substance prevents the AIDS viruses from gaining access to the immune cells that they would otherwise infect."
The Verband Forschender Arzneimittelhersteller (vfa) or Association of Research-Based Pharmaceutical Companies, is the trade group of 43 pharmaceutical companies in Germany which are global players, representing more than two-thirds of the German pharmaceutical market, with nearly 80,000 employees in Germany...including the following eight largest global pharmaceutical companies with 2014 pharm sales in brackets: Novartis (51.3B$), Pfizer (44.9B$), Sanofi (40B$), Roche (37.6B$), Merck (36.6B$), Johnson&Johnson (36.4B$), AstraZeneca (33.3B$) and GlaxoSmithKline (31.5B$). https://en.wikipedia.org/wiki/Verband_Forsche...hersteller
https://www.vfa.de/de/englische-inhalte/thera...s-covid-19
17. January 2021
Therapeutic medicines against the coronavirus infection Covid-19
"The active ingredient Leronlimab from CytoDyn is a CCR5 antagonist, it blocks a receptor on the surface of certain immune cells. In a phase II trial, it was shown to improve the health of mild to moderate Covid-19 patients. The manufacturer then conducted a Phase III trial in patients with severe disease and applied to the FDA for emergency use approval. Until a decision is made, new patients with severe symptoms at the hospitals that participated in the trial can be treated with Leronlimab. The company is also testing whether Leronlimab will improve late symptoms in Covid 19 patients who have had the infection for a long time. The antibody Leronlimab has long been developed for the treatment of HIV and triple-negative breast cancer, for which it is already being tested in trials. However, its efficacy against HIV is not based on attenuating immunomodulation, but on the fact that the active substance prevents the AIDS viruses from gaining access to the immune cells that they would otherwise infect."
The Verband Forschender Arzneimittelhersteller (vfa) or Association of Research-Based Pharmaceutical Companies, is the trade group of 43 pharmaceutical companies in Germany which are global players, representing more than two-thirds of the German pharmaceutical market, with nearly 80,000 employees in Germany...including the following eight largest global pharmaceutical companies with 2014 pharm sales in brackets: Novartis (51.3B$), Pfizer (44.9B$), Sanofi (40B$), Roche (37.6B$), Merck (36.6B$), Johnson&Johnson (36.4B$), AstraZeneca (33.3B$) and GlaxoSmithKline (31.5B$). https://en.wikipedia.org/wiki/Verband_Forsche...hersteller
(5)
(0)Scroll down for more posts ▼
